TY  - JOUR
AU  - Prat, Aleix
AU  - Lluch, Ana
AU  - Turnbull, Arran K
AU  - Dunbier, Anita K
AU  - Calvo, Lourdes
AU  - Albanell, Joan
AU  - de la Haba-Rodriguez, Juan
AU  - Arcusa, Angels
AU  - Chacon, Jose Ignacio
AU  - Sanchez-Rovira, Pedro
AU  - Plazaola, Arrate
AU  - Muñoz, Montserrat
AU  - Pare, Laia
AU  - Parker, Joel S
AU  - Ribelles, Nuria
AU  - Jimenez, Begoña
AU  - Bin Aiderus, Abdul Aziz
AU  - Caballero, Rosalia
AU  - Adamo, Barbara
AU  - Dowsett, Mitch
AU  - Carrasco, Eva
AU  - Martin, Miguel
AU  - Dixon, J Michael
AU  - Perou, Charles M
AU  - Alba, Emilio
PY  - 2016
DO  - 10.1158/1078-0432.CCR-16-2092
UR  - http://hdl.handle.net/10668/10654
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - Purpose: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous, and subgroups with different prognostic and treatment sensitivities need to be identified.Experimental Design: Research-based PAM50 subtyping and...
LA  - en
PB  - American Association for Cancer Research
KW  - Aged
KW  - Antineoplastic agents, hormonal
KW  - Breast neoplasms
KW  - Female
KW  - Gene expression regulation, neoplastic
KW  - Humans
KW  - Middle aged
KW  - Neoadjuvant therapy
KW  - Neoplasm proteins
KW  - Neoplasm recurrence, local
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - Receptors, estrogen
KW  - Receptors, progesterone
KW  - Recurrence
TI  - A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
TY  - Research article
VL  - 23
ER  -